

July 30, 2015

# **Ultralife Corporation Reports Second Quarter Results**

NEWARK, N.Y., July 30, 2015 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating income of \$0.8 million on revenue of \$19.0 million for the quarter ended June 28, 2015. For the second quarter of 2014, the Company reported an operating loss of \$1.3 million on revenue of \$15.2 million.

"Our second quarter results demonstrate the operating leverage inherent in our business model and the success of our strategy to invest in new products, customers, markets and geographies. Following a strong first quarter performance, we delivered another quarter of 25% revenue growth and substantial gains in profitability marked by a consolidated gross margin of 31%, an operating margin of 4.3%, and an EPS of \$0.05," said Michael D. Popielec, Ultralife's President and Chief Executive Officer. "At the mid-point of the year with revenue growth of 25% and EPS improvement of \$0.23 over the first half of 2014, we have increasing confidence in our outlook for top-line growth and profitable results for 2015."

### Second Quarter 2015 Financial Results

Revenue grew 25%, or \$3.8 million, to \$19.0 million from \$15.2 million for the second quarter of 2014 driven by gains in Battery & Energy Product sales. Battery & Energy Products sales were \$16.0 million, compared to \$12.2 million last year, a 31% increase, primarily due to higher shipments to Government/Defense customers. Communications Systems sales were \$3.0 million, flat with the same period last year.

Gross profit grew 39% to \$5.9 million from \$4.2 million for the second quarter a year ago. As a percentage of revenue, gross profit increased 320 basis points to 30.9% from 27.7% last year, primarily reflecting favorable mix of higher gross margin products and improved overhead absorption on higher sales volumes. Battery & Energy Products' gross margin was 28.4%, compared to 23.6% last year, an increase of 480 basis points. Communications Systems' gross margin was 44.2%, compared to 44.0% last year, an increase of 20 basis points.

Operating expenses declined 9%, or \$0.5 million, to \$5.0 million from \$5.5 million a year ago. As a percentage of revenue, operating expenses were 26.6%, compared to 36.4% a year ago.

Higher revenue combined with the leverage of improved gross margin and lower operating expenses resulted in operating income of \$0.8 million, compared to an operating loss of \$1.3 million for the second quarter of 2014, an improvement of \$2.1 million. Operating margin was 4.3%, compared to (8.7)% for the year-earlier period.

Net income from continuing operations was \$0.8 million, or \$0.05 per share, compared to a net loss of \$1.4 million, or \$0.08 per share, for the second quarter of 2014.

### Share Repurchase Program

During the second quarter, Ultralife repurchased 1,398,454 shares under its 3.4 million share repurchase program, which will end April 30, 2016. Since the inception of the share repurchase program on May 1, 2014, the Company has repurchased 1,941,691 shares.

### **About Ultralife Corporation**

Ultralife Corporation serves its markets with products and services ranging from power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government, defense and commercial customers across the globe.

Headquartered in Newark, New York, the Company's business segments include Battery & Energy Products and Communications Systems. Ultralife has operations in North America, Europe and Asia. For more information, visit www.ultralifecorporation.com.

### **Conference Call Information**

Ultralife will hold its second quarter earnings conference call today at 10:00 AM ET. To participate in the live call, please dial (800) 915-4836 at least ten minutes before the scheduled start time, identify yourself and ask for the Ultralife call. A live webcast of the conference call will be available to investors in the Events & Presentations section of the Company's website at

<u>http://investor.ultralifecorporation.com</u>. For those who cannot listen to the live broadcast, a replay of the webcast will be available shortly after the call at the same location.

This press release may contain forward-looking statements based on current expectations that involve a number of risks and uncertainties. The potential risks and uncertainties that could cause actual results to differ materially include potential reductions in U.S. military spending, uncertain global economic conditions and acceptance of our new products on a global basis. The Company cautions investors not to place undue reliance on forward-looking statements, which reflect the Company's analysis only as of today's date. The Company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances. Further information on these factors and other factors that could affect Ultralife's financial results is included in Ultralife's Securities and Exchange Commission (SEC) filings, including the latest Annual Report on Form 10-K.

## ULTRALIFE CORPORATION AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (Dollars in Thousands) (unaudited)

#### ASSETS

	June 28, December 31,		
		2014	
Current assets:			
Cash and cash equivalents	\$ 15,932	\$ 17,866	
Trade accounts receivable, net	11,293	11,295	
Inventories	24,000	26,086	
Prepaid expenses and other current assets	1,412	1,603	
Total current assets	52,637	56,850	
Property, equipment and improvements, net	9,501	9,812	
Goodwill, intangibles and other assets	20,797	20,980	
Total assets	\$ 82,935	\$ 87,642	

#### LIABILITIES AND SHAREHOLDERS' EQUITY

. . . . . . . . .

Current liabilities:		
Accounts payable	\$ 6,353	\$ 6,996
Accrued compensation and related benefits	2,388	1,725
Accrued expenses and other current liabilities	1,865	2,490
Total current liabilities	10,606	11,211
Deferred income taxes and other non-current liabilities	4,628	4,518
Total liabilities	15,234	15,729
Shareholders' equity:		
Common stock	1,897	1,894
Capital in excess of par value	176,249	175,940
Accumulated deficit	(95,599)	(96,920)
Accumulated other comprehensive loss	(401)	(467)
Treasury stock	(14,307)	(8,420)
Total Ultralife equity	67,839	72,027
Noncontrolling interest	(138)	(114)
Total shareholders' equity	67,701	71,913

Total

## ULTRALIFE CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (In Thousands except per share amounts) (unaudited)

June 28, 2015     June 28, 2014     June 28, 2014     June 28,		Three month p	Three month periods ended		riods ended
Revenues:		June 28,	June 29,	June 28,	June 29,
Battery & energy products   \$ 15,972   \$ 12,165   \$ 32,248   \$ 26,087     Communication systems   2,983   3,034   5,884   4,397     Total revenues   18,955   15,199   \$33,132   \$30,444     Cost of products sold:   11,430   9,289   22,922   19,410     Communication systems   1,666   1,698   3,344   2,527     Total cost of products sold   13,096   10,987   22,626   21,937     Gross profit   5,859   4,212   11,866   8,547     Operating expenses:   Research and development   1,334   1,560   2,693   2,996     Selling, general and administrative   3,708   3,976   7,534   7,971     Total coperating income (loss)   817   (1,324)   1,639   (2,420)     Interest and other (expense) income, net   28   5   (160)   (56)     Income (loss) from continuing operations before income taxes   845   (1,319)   1,479   (2,478)     Income (loss) from continuing operations   774   (1,376)   1,297   (2,659)     Loss from discontinued operations, net		2015	2014	2015	2014
Communication systems     2.983     3.034     5.884     4.397       Total revenues     18,955     15,199     \$38,132     \$30,484       Cost of products sold:     11,430     9,289     22,922     19,410       Communication systems     1,666     1,698     3,344     2,527       Total cost of products sold     13,096     10,997     26,266     21,937       Gross profit     5,859     4,212     11,866     8,547       Operating expenses:     Research and development     1,334     1,560     2,693     2,996       Selling, general and administrative     3,708     3,976     7,534     7,971       Total coperating expenses:     5,042     5,536     10,227     10,967       Operating income (loss)     817     (1,324)     1,639     (2,420)       Interest and other (expense) income, net     28     5     (160)     (58)       Income (loss) from continuing operations     774     (1,376)     1,297     (2,595)       Loss from discontinued operations, net of tax       (61) <	Revenues:				
Total revenues   18.955   15.199   \$38.132   \$30.484     Cost of products sold:  <	Battery & energy products	\$ 15,972	\$ 12,165	\$ 32,248	\$ 26,087
Cost of products sold:       Battery & energy products     11,430     9,289     22,922     19,410       Communication systems     11,666     16.898     3,344     2,527       Total cost of products sold     13.096     10,987     26,266     21,937       Gross profit     5.859     4,212     11,866     8,547       Operating expenses:       3,706     7,534     7,971       Total operating expenses     5,042     5,536     10,227     10,967       Selling, general and administrative     3,708     3,976     7,534     7,971       Total operating expenses     5,042     5,536     10,227     10,967       Operating income (loss)     817     (1,324)     1,639     (2,420)       Interest and other (expense) income, net     28     5     (160)     (58)       Income (loss) from continuing operations before income taxes     845     (1,319)     1,479     (2,478)       Income (loss) from continuing operations     774     (1,376)     1,297     (2,559)       Loss from discontinued operations, net o	Communication systems	2,983	3,034	5,884	4,397
Battery & energy products   11,430   9,289   22,922   19,410     Communication systems   1,666   1,698   3,344   2,527     Total cost of products sold   13,096   10,987   26,266   21,937     Gross profit   5,859   4,212   11,866   8,547     Operating expenses:     3,708   3,976   7,534   7,971     Total operating expenses:   3,708   3,976   7,534   7,971   Total operating expenses   5,042   5,536   10,227   10,967     Operating income (loss)   817   (1,324)   1,639   (2,420)     Interest and other (expense) income, net   28   5   (160)   (58)     Income (loss) from continuing operations   71   57   182   117     Net income (loss) from continuing operations, net of tax     (61)     Net income (loss) producting interest   14   16   24   10     Net income (loss) per share attributable to Ultralife common shareholders - basic:   S (1,360)   \$ 1,321   \$ (2,666)     Net income (loss) per share attributable to Ultralife common shareholders - b	Total revenues	18,955	15,199	\$38,132	\$30,484
Communication systems     1.666     1.698     3.344     2.527       Total cost of products sold     13.096     10.987     26.266     21,337       Gross profit     5.859     4.212     11.866     8.547       Operating expenses:           Research and development     1.334     1.560     2.693     2.996       Selling, general and administrative     3.708     3.976     7.534     7.971       Total operating expenses     5.042     5.538     10.227     10.967       Operating income (loss)     817     (1.324)     1.639     (2.420)       Interest and other (expense) income, net     28     5     (160)     (58)       Income (loss) from continuing operations before income taxes     845     (1.319)     1.479     (2.420)       Income (loss) from continuing operations     774     (1.376)     1.297     (2.595)       Loss from discontinued operations, net of tax       (61)       Net income (loss) attributable to Ultralife     \$786     \$(1.360)     \$1.321     \$(2.646)	Cost of products sold:				
Total cost of products sold     13,096     10,987     26,266     21,937       Gross profit     5,859     4,212     11,866     8,547       Operating expenses:     Research and development     1,334     1,560     2,693     2,996       Selling, general and administrative     3,708     3,976     7,534     7,971       Total operating expenses     5,042     5,536     10,227     10,967       Operating income (loss)     817     (1,324)     1,639     (2,420)       Interest and other (expense) income, net     28     5     (160)     (58)       Income (loss) from continuing operations before income taxes     845     (1,319)     1,479     (2,478)       Income (loss) from continuing operations     774     (1,376)     1,297     (2,595)       Loss from discontinued operations, net of tax       (61)       Net income (loss)     774     (1,376)     1,297     (2,656)       Net income (loss) attributable to Ultralife     \$788     \$(1,360)     \$1,321     \$(2,646)       Net income (loss) per share attributable to Ultralife common	Battery & energy products	11,430	9,289	22,922	19,410
Gross profit     5,859     4,212     11,866     8,547       Operating expenses:     Research and development     1,334     1,560     2,693     2,996       Selling, general and administrative     3,708     3,976     7,534     7,971       Total operating expenses     5,042     5,536     10,227     10,967       Operating income (loss)     817     (1,324)     1,639     (2,420)       Interest and other (expense) income, net     28     5     (160)     (58)       Income (loss) from continuing operations before income taxes     845     (1,319)     1,479     (2,478)       Income (loss) from continuing operations     771     57     182     117       Net income (loss) from continuing operations     774     (1,376)     1,297     (2,656)       Net income (loss)     774     (1,376)     1,297     (2,656)     (2,656)       Net income (loss) attributable to Ultralife     \$788     \$(1,360)     \$1,321     \$(2,646)       Net income (loss) per share attributable to Ultralife common shareholders - basic:     \$.05     \$(.08)     \$.08     \$(.15)	Communication systems	1,666	1,698	3,344	2,527
Operating expenses:       Research and development     1,334     1,560     2,693     2,996       Selling, general and administrative     3,708     3,976     7,534     7,971       Total operating expenses     5,042     5,536     10,227     10,967       Operating income (loss)     817     (1,324)     1,639     (2,420)       Interest and other (expense) income, net     28     5     (160)     (58)       Income (loss) from continuing operations before income taxes     845     (1,319)     1,479     (2,478)       Income (loss) from continuing operations     71     57     182     117       Net income (loss) from continuing operations     774     (1,376)     1,297     (2,595)       Loss from discontinued operations, net of tax        (61)       Net income (loss)     attributable to ultralife     \$788     \$(1,360)     \$1,321     \$(2,646)       Net income (loss) per share attributable to Ultralife common shareholders - basic:     \$.05     \$(.08)     \$.08     \$(.15)	Total cost of products sold	13,096	10,987	26,266	21,937
Research and development   1,334   1,560   2,693   2,996     Selling, general and administrative   3,708   3,976   7,534   7,971     Total operating expenses   5,042   5,536   10,227   10,967     Operating income (loss)   817   (1,324)   1,639   (2,420)     Interest and other (expense) income, net   28   5   (160)   (58)     Income (loss) from continuing operations before income taxes   845   (1,319)   1,479   (2,478)     Income (loss) from continuing operations   71   57   182   117     Net income (loss) from continuing operations, net of tax     (61)     Net loss attributable to non-controlling interest   14   16   24   10     Net income (loss) attributable to Ultralife   \$788   \$(1,360)   \$1,321   \$(2,646)     Net income (loss) per share attributable to Ultralife common shareholders - basic:   \$.05   \$(.08)   \$.08   \$(.15)	Gross profit	5,859	4,212	11,866	8,547
Selling, general and administrative   3,708   3,976   7,534   7,971     Total operating expenses   5,042   5,536   10,227   10,967     Operating income (loss)   817   (1,324)   1,639   (2,420)     Interest and other (expense) income, net   28   5   (160)   (58)     Income (loss) from continuing operations before income taxes   845   (1,319)   1,479   (2,478)     Income tax provision   71   57   182   117     Net income (loss) from continuing operations   774   (1,376)   1,297   (2,595)     Loss from discontinued operations, net of tax     (61)     Net income (loss)   1,297   (2,656)   1,297   (2,656)     Net loss attributable to non-controlling interest   14   16   24   10     Net income (loss) per share attributable to Ultralife common shareholders - basic:   \$.05   \$ (.08)   \$ .08   \$ (.15)	Operating expenses:				
Total operating expenses     5,042     5,536     10,227     10,967       Operating income (loss)     817     (1,324)     1,639     (2,420)       Interest and other (expense) income, net     28     5     (160)     (58)       Income (loss) from continuing operations before income taxes     845     (1,319)     1,479     (2,478)       Income (loss) from continuing operations     71     57     182     117       Net income (loss) from continuing operations, net of tax       (61)       Net income (loss)     774     (1,376)     1,297     (2,656)       Net loss attributable to non-controlling interest     14     16     24     10       Net income (loss) per share attributable to Ultralife     \$788     \$(1,360)     \$1,321     \$(2,646)       Net income (loss) per share attributable to Ultralife common shareholders - basic:     \$.05     \$(.08)     \$.08     \$(.15)	Research and development	1,334	1,560	2,693	2,996
Operating income (loss)   817   (1,324)   1,639   (2,420)     Interest and other (expense) income, net   28   5   (160)   (58)     Income (loss) from continuing operations before income taxes   845   (1,319)   1,479   (2,478)     Income (loss) from continuing operations   71   57   182   117     Net income (loss) from continuing operations, net of tax     (61)     Net income (loss)   774   (1,376)   1,297   (2,656)     Net loss attributable to non-controlling interest   14   16   24   10     Net income (loss) per share attributable to Ultralife common shareholders - basic:   \$.05   \$ (.08)   \$ .08   \$ (.15)	Selling, general and administrative	3,708	3,976	7,534	7,971
Interest and other (expense) income, net $28$ $5$ $(160)$ $(58)$ Income (loss) from continuing operations before income taxes $845$ $(1,319)$ $1,479$ $(2,478)$ Income tax provision $71$ $57$ $182$ $117$ Net income (loss) from continuing operations $774$ $(1,376)$ $1,297$ $(2,595)$ Loss from discontinued operations, net of tax $$ $$ $$ $(61)$ Net income (loss) $774$ $(1,376)$ $1,297$ $(2,656)$ Net loss attributable to non-controlling interest $14$ $16$ $24$ $10$ Net income (loss) per share attributable to Ultralife common shareholders - basic: Continuing operations $\$,05$ $\$,(08)$ $\$,08$ $\$,(.15)$	Total operating expenses	5,042	5,536	10,227	10,967
Income (loss) from continuing operations before income taxes845(1,319)1,479(2,478)Income tax provision7157182117Net income (loss) from continuing operations774(1,376)1,297(2,595)Loss from discontinued operations, net of tax(61)Net income (loss)774(1,376)1,297(2,656)Net income (loss)774(1,376)1,297(2,656)Net loss attributable to non-controlling interest14162410Net income (loss) per share attributable to Ultralife common shareholders - basic: Continuing operations\$.05\$(.08)\$.08\$(.15)	Operating income (loss)	817	(1,324)	1,639	(2,420)
Income tax provision7157182117Net income (loss) from continuing operations774(1,376)1,297(2,595)Loss from discontinued operations, net of tax(61)Net income (loss)774(1,376)1,297(2,656)Net loss attributable to non-controlling interest14162410Net income (loss) attributable to Ultralife\$788\$(1,360)\$1,321\$(2,646)Net income (loss) per share attributable to Ultralife common shareholders - basic: Continuing operations\$.05\$(.08)\$.08\$(.15)	Interest and other (expense) income, net	28	5	(160)	(58)
Net income (loss) from continuing operations774(1,376)1,297(2,595)Loss from discontinued operations, net of tax(61)Net income (loss)774(1,376)1,297(2,656)Net loss attributable to non-controlling interest14162410Net income (loss) attributable to Ultralife\$788\$(1,360)\$1,321\$(2,646)Net income (loss) per share attributable to Ultralife common shareholders - basic: Continuing operations\$.05\$(.08)\$.08\$(.15)	Income (loss) from continuing operations before income taxes	845	(1,319)	1,479	(2,478)
Loss from discontinued operations, net of tax(61)Net income (loss)774(1,376)1,297(2,656)Net loss attributable to non-controlling interest14162410Net income (loss) attributable to Ultralife\$788\$(1,360)\$1,321\$(2,646)Net income (loss) per share attributable to Ultralife common shareholders - basic: Continuing operations\$.05\$(.08)\$.08\$(.15)	Income tax provision	71	57	182	117
Net income (loss)774(1,376)1,297(2,656)Net loss attributable to non-controlling interest14162410Net income (loss) attributable to Ultralife\$788\$(1,360)\$1,321\$(2,646)Net income (loss) per share attributable to Ultralife common shareholders - basic: Continuing operations\$.05\$(.08)\$.08\$(.15)	Net income (loss) from continuing operations	774	(1,376)	1,297	(2,595)
Net loss attributable to non-controlling interest   14   16   24   10     Net income (loss) attributable to Ultralife   \$788   \$(1,360)   \$1,321   \$(2,646)     Net income (loss) per share attributable to Ultralife common shareholders - basic:   \$.05   \$(.08)   \$.08   \$(.15)	Loss from discontinued operations, net of tax	<u> </u>	<u> </u>		(61)
Net income (loss) attributable to Ultralife   \$ 788   \$ (1,360)   \$ 1,321   \$ (2,646)     Net income (loss) per share attributable to Ultralife common shareholders - basic:   Continuing operations   \$ .05   \$ (.08)   \$ .08   \$ (.15)	Net income (loss)	774	(1,376)	1,297	(2,656)
Net income (loss) per share attributable to Ultralife common shareholders - basic:     Continuing operations   \$ .05   \$ (.08)   \$ .08   \$ (.15)	Net loss attributable to non-controlling interest	14	16	24	10
Continuing operations     \$ .05     \$ (.08)     \$ .08     \$ (.15)	Net income (loss) attributable to Ultralife	\$ 788	\$ (1,360)	\$ 1,321	\$ (2,646)
	Net income (loss) per share attributable to Ultralife common shareholders - basic:				
Discontinued operations (.00)	Continuing operations	\$ .05	\$ (.08)	\$ .08	\$ (.15)
	Discontinued operations	<u> </u>			(.00)

\$ .05

\$ (.08)

\$.08

\$ (.15)

Net income per share attributable to Ultralife common shareholders - diluted:				
Continuing operations	\$ .05		\$ .08	
Discontinued operations		_		
Total	\$ .05	=	\$ .08	
Weighted average shares outstanding - basic	16,557	17,533	16,945	17,523
Weighted average shares outstanding - diluted	16,597	=	16,977	

CONTACT: Company Contact:

Ultralife Corporation

Philip A. Fain

(315) 332-7100

pfain@ulbi.com

Investor Relations Contact:

LHA

Jody Burfening

(212) 838-3777

jburfening@lhai.com